EOLS Stock — Evolus Inc.: Cash, EV, Pipeline

What they do

We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products.

Source: 10-K FY2025 via SEC EDGAR

Share price

$6.80

Market cap

$450.4M

Cash

$41.7M

Enterprise value

$565.6M

Balance sheet

Cash	$41.7M
Debt	$156.9M
Net cash	-$115.2M
Enterprise value	$565.6M
Basic shares	66.2M shares
Fully diluted shares	80.6M shares
Fully diluted market cap	$548.0M
Cash per share	$0.63
Quarterly burn	$3.6M
Cash runway	12.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

66.0M

Pre-funded warrants

0.0M

Options

6.8M

RSUs

6.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.1M

FDSO

80.6M

Cap table as of 2026-06-30.

Price history

Loading EOLS daily closes…

Loading price history…

Next catalyst

Evolysse Sculpt · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	Evolysse Sculpt	Not disclosed	Not disclosed	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Jeuveau

Approved · Active Modality: Injectable (botulinum toxin)

Aliases prabotulinumtoxinA-xvfs, Nuceiva (Canada/Europe/Australia)

Partnerships Daewoong: license agreement (manufacture/supply); Medytox: settlement agreements governing rights to market/sell Jeuveau

Indications

Facial aesthetics (glabellar lines) (Approved)

Status note Approved aesthetic neurotoxin; marketed in US, Canada, Europe, Australia. Company depends on Daewoong/Medytox/Symatese agreements for supply and distribution rights.

Evolysse

Approved · Active Modality: Injectable hyaluronic acid (HA) gel

Aliases Estyme (ex-US), Evolysse Form, Evolysse Smooth

Partnerships Symatese: exclusive US rights (Apr 2025 launch of Evolysse Form/Smooth; Lips/Eye products in US registration; cost-sharing on FDA registration) + exclusive rights in 50 European countries (four products launched May 2026; MDR approval Oct 2024); milestone payments (up to ~16.2M EUR US + EUR 1.2M/1.9M EU) + royalties; Symatese is sole supplier

Indications

Aesthetic/dermatological dermal filler (Approved)

Status note Injectable HA gel dermal filler line; FDA-approved products launched US Apr 2025, EU May 2026. Lips and Eye products under US registration.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06903975	Not disclosed	Recruiting	Collaborator	Boston Medical Center	—	Neck Muscle Issue	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Boston Medical Center on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	3,155,209	+50,000	0.81%	2026-08-14
Frazier Life Sciences	2,630,665	no change	0.40%	2026-08-14
Perceptive Advisors	2,459,285	+1,172,423	0.27%	2026-08-14
Stonepine Capital	1,590,162	-168,929	8.40%	2026-08-17
ADAR1 Capital Management	100,000	+44,141	0.03%	2026-08-14
Tang Capital Partners	0	-483,021	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

EOLS — Evolus Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

EOLS — Evolus Inc.